Skip to main content

Clinuvel Pharmaceuticals Value Stock - Dividend - Research Selection

Clinuvel Pharmaceuticals

ISIN: AU000000CUV3, WKN: A0JEGY

Market price date: 16.07.2021
Market price: 27,37 AUD




Clinuvel Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in AUD
Key figures 04-09-2020
Cash flow
Net operating cash flow 14.188.000
Capital Expenditures -888.826
Free cash flow 13.299.542
Balance sheet
Total Equity 73.668.000
Liabilities & Shareholders equity 82.000.000
Income statement
Net income 16.646.000
Eps (diluted) 0,330
Diluted shares outstanding 50.458.000
Net sales/revenue 32.565.000

Fundamental ratios calculated on: 16-07-2021

Ratios
Key figures 16-07-2021
Cash flow
P/C 97,34
   
P/FC 103,84
Balance sheet
ROI20,30
ROE89,84
Income statement
P/E82,94
Div. Yield0,00%
P/B18,75
P/S42,41


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolCLVLY
Market Capitalization1.060.051.776,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceIFRS in Millionen AUD
Stock Split2010-11-12,1.000000/10.000000
Internetwww.clinuvel.com


Description of the company

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company\'s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.clinuvel.com